Jeffrey Bluestone, PhD

Phone: 415-476-4451
UCSF Box: 0400
Email: [email protected]
UCSF Profile

Project Sponsor
 		Location(s) Topics Start End
Coolscope Digital Microscope and Virtual Slide Software Suite Nikon, Inc. United States
Determination and optimization of the mechanism of action for efficacy of Gleevec in the type I diabetes NOD mouse model Genomics Inst of the Novartis Resrch Fdn United States Diabetes
UCSF Comprehensive Center for Immunologic Diseases (CCID) Feder'n of Clinical Immunology Societies United States Immunology
The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation European Commission United States Immunology
Repertoire analysis of T cells in T1D Benaroya Research Inst at Virginia Mason United States Diabetes
Tolerance induction using engineered stem cell-specific regulatory T cells California Institute for Regenerative Medicine United States Diabetes
Development of Regulatory T-Cells for Treatment of Autoimmune Disease Becton, Dickinson, and Company United States Immunology, Pharmacology and Drug Treatment
Peking Union Medical College Hospital (PUMCH) Strategic Partnership Peking Union Medical College Hospital China Health Systems Strengthening, Training International Scholars and Clinicians, Residencies, Fellowships, and Postdoctoral Training
CD4+ FoxP3 lineage cells in CNS autoimmune disease and therapy National Multiple Sclerosis Society United States
Use of CHIP-CHIP Technology to Identify Target Genes for Foxp3 Regulatory T Cells University of Colorado Denver, Anschutz Medical Campus United States Diabetes
CD101 DC Subsets in T1D University of Colorado Denver, Anschutz Medical Campus United States Diabetes
B7/CD18/CTLA-4 Costimulation in the Pathogenesis of R-EAE Northwestern University United States
JDRF Islet Transplantation Center at UCSF and U of Minn Juvenile Diabetes Research Foundation International United States Diabetes
Multiple Approach to Study Type 1 Diabetes with Residual C-Peptide University of Michigan United States Diabetes
Brehm Coalition - Type 1 Diabetes Research University of Michigan United States Diabetes
Immune modulation for the treatment of type 1 diabetes American Diabetes Association, Inc. United States Diabetes
Phase II Double Blinded, Placebo-Controlled, Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab, an Anti-IgE mAb Genentech, Inc. United States Immunology
Role of Innate Lymphoid Cells in Autoimmunity NIH National Institute of Allergy and Infectious Disease United States Diabetes
Spontaneous Autoimmune Model of Peripheral Neuropathy NIH National Institute of Allergy and Infectious Disease United States Diabetes
Collaborative Network for Clinical Research on Immune Tolerance - Offcampus Portion NIH National Institute of Allergy and Infectious Disease United States Diabetes, Immunology
Collaborative Network for Clinical Research on Immune Tolerance NIH National Institute of Allergy and Infectious Disease United States Diabetes, Immunology
Immunomodulation of transplant rejection by anti-CD3 mAb NIH National Institute of Allergy and Infectious Disease United States Immunology
Spontaneous Autoimmune Model of Peripheral Neuropathy NIH National Institute of Allergy and Infectious Disease United States Diabetes
Role of Notch 1 in Immunie Tolerance NIH National Institute of Allergy and Infectious Disease United States Noncommunicable and/or Chronic Disease
Immunomodulation of Transplant Rejection by Anti-CD3 mAb NIH National Institute of Allergy and Infectious Disease United States Noncommunicable and/or Chronic Disease
Immunomodulation of Transplant Rejection by Anti-CD3 mAb NIH National Institute of Allergy and Infectious Disease United States Surgery and Anesthesia
Spontaneous Autoimmune Model of Peripheral Neuropathy NIH National Institute of Allergy and Infectious Disease United States Diabetes, Risk Reduction and Prevention
Role of innate immune system on Treg programming in human autoimmune disease Yale University United States Diabetes
Safety & Efficacy of Abatacept in Adults with Relapsing-Remitting Multiple Sclerosis Bristol-Myers Squibb Company United States
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy &Safety of Atorvastatin in Patients w/ Clinically Isolated Syndrome & High Risk for Conversion to M.S. Pfizer United States Neurology and Mental Health
Review of SFPHD Research Studies Involving Human Subject City and County of San Francisco United States
Antigen Specificity of Regulatory T cells in Type 1 diabetes T1D United States Diabetes, Immunology